BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …

Major advances in pulmonary arterial hypertension, pulmonary hypertension (PH)
associated with lung disease, and chronic thromboembolic PH cast new light on the …

Social determinants of health (SDoH) can impact the vulnerable pulmonary arterial
hypertension (PAH) population, especially during the COVID‐19 pandemic. Providers' …

Conflict of interest statements: Dr RJ Bernardo serves on the medical advisory board for
Janssen Pharmaceuticals. Dr VA de Jesus Perez has no conflict of interest to declare …

Pulmonary arterial hypertension (PAH) is a rare, complex, and deadly cardiopulmonary
disease. It is characterized by changes in endothelial cell function and smooth muscle cell …

Background Emerging data suggest that Hispanic patients with pulmonary arterial
hypertension (PAH) exhibit improved survival rates compared to individuals of other …

Rationale: Pulmonary arterial hypertension (PAH) is a heterogeneous disease within a
complex diagnostic and treatment environment. Other complex heart and lung diseases …

We read with great interest the article “Social determinants of health in pulmonary arterial
hypertension patients in the United States: Clinician perspective and health policy …

To better understand the impact of the COVID‐19 pandemic on the care of patients with
pulmonary hypertension, we conducted a retrospective cohort study evaluating health …

Objectives The comparative efficacy between riociguat and selexipag in patients with
pulmonary arterial hypertension (PAH) has never been described in literature. Our aim was …